In a recent report, Jefferies has raised the price target on Amarin AMRN from $21.00 to $25.00 after a AMR101 patent discussion with the FDA.
In the report, Jefferies said, "We believe a longer-than-expected Hatch-Waxman patent extension of 5 years (vs. company guidance of 2 years) could extend AMR101 U.S. market exclusivity from 2022 to 2025."
Amarin closed Friday at $17.00.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst Ratingsamarin corporationHealth CareJefferiesPharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in